Concepedia

Stephen A. St-Gallay

SA

Statistics

Publications

16

Citations

978

H-Index

13

Active since

2004

Affiliations

AstraZeneca (United Kingdom)(Current)

Loughborough University

AstraZeneca (Sweden)

Scripps Research Institute

Liverpool John Moores University

Stephen A. St-Gallay is an author at AstraZeneca (United Kingdom) specializing in drug discovery, pharmacy, and medicinal chemistry.

ORCID

Publications per year

2004–2019

16

Publications

16

Anchored plasticity opens doors for selective inhibitor design in nitric oxide synthase

Elsa D. Garcin, A.S. Arvai, R.J. Rosenfeld et al. · Nature Chemical Biology · 2008 · 270 citations · Full text

, , +12

Structure-Based Design of Potent and Selective Inhibitors of the Metabolic Kinase PFKFB3

Scott Boyd, Joanna Brookfield, Susan E. Critchlow et al. · Journal of Medicinal Chemistry · 2015 · 96 citations · Full text

, , +15

Hit-to-lead studies: the discovery of potent, orally active, thiophenecarboxamide IKK-2 inhibitors

Andrew Baxter, Steve Brough, Anne Cooper et al. · Bioorganic & Medicinal Chemistry Letters · 2004 · 91 citations

, , +14

Impact of ion class and time on oral drug molecular properties

Paul D. Leeson, Stephen A. St-Gallay, Mark C. Wenlock · MedChemComm · 2010 · 83 citations

, , +10

WizePairZ: A Novel Algorithm to Identify, Encode, and Exploit Matched Molecular Pairs with Unspecified Cores in Medicinal Chemistry

Daniel J. Warner, Ed Griffen, Stephen A. St-Gallay · Journal of Chemical Information and Modeling · 2010 · 72 citations

, , +15

1–5 of 16